Gerard Marek

Chief Medical Officer

Boehringer Ingelheim Pharmaceuticals Inc

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Gerard Marek is the Chief Medical Officer at Gilgamesh Pharmaceuticals, Inc. in the United States. His research primarily focuses on pharmacokinetics and the safety and efficacy of novel pharmaceutical compounds, particularly in the areas of depression, opioid interaction, and neuropharmacology. Notable recent articles include investigations of the NMDA receptor antagonist GM-1020 and various studies on the GABA B receptor positive allosteric modulator ASP8062.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (1)

Zoe Hughes

VP, Head of Biology

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Gerard Marek

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents.

A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA<sub>B</sub> receptor, and morphine in recreational opioid users.

A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.

A phase 1 study to assess potential interaction between ASP8062 and alcohol in healthy adult subjects.

Single- and multiple-dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator-activated receptor delta in healthy adults: Results from a phase 1 study.

Cortical influences of serotonin and glutamate on layer V pyramidal neurons.

A randomized phase 1 single-dose polysomnography study of ASP8062, a GABA<sub>B</sub> receptor positive allosteric modulator.

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies.

Efficacy and Safety of ASP0819 in Patients with Fibromyalgia: Results of a Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D<sub>1</sub> receptor positive allosteric modulator in patients with schizophrenia.

Collaborators (1)

Zoe Hughes

Make your next move.